#small-cell lung cancer

[persephoneflouwers]

This tiktok was on my fyp. Since I’m a very goodhearted soul I share life important news with people I care about

[bpod-bpod]

Many Mini Maps

The environment in and around a tumour is like a hostile school lunch hall, with some cliques clumping together while free spirits and nervous new starters scatter among spare seats. The tumour environment houses cancer cells but also countless immune cells and other materials either co-opted to the cancer’s cause or dragged in as bystanders. Mapping the distribution of these cell types might reveal new lines of approach for treatments. A study placed 23 molecular markers on many non-small cell lung cancer samples (pictured) and found that some protective immune cells cluster together while cells suppressing immune activity mix more evenly. With proximity to cancer cells, the distribution patterns changed, and the team found a link between the cell layouts and survival outcomes, suggesting that these maps could point the way to better understanding of a patient’s tumour microenvironment, more accurate analysis of tumours, and even new forms of treatment.

Written by Anthony Lewis

Image adapted from work by Edwin Roger Parra and colleagues

Departments of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Image originally published with a Creative Commons Attribution 4.0 International (CC BY 4.0)

Published in Nature Communications, April 2023

You can also follow BPoD on Instagram, Twitter and Facebook

[industryexperts]

(via Global Lung Cancer Therapeutics Market | Trends, Forecast 2024-2030)

The lung cancer therapeutics market in 2024 is dominated by the non-small cell lung cancer (NSCLC) type, which holds an estimated 85.3% share due to its high prevalence and the development of targeted therapies and immunotherapies. These advancements specifically target genetic mutations such as EGFR, ALK, and ROS1, providing personalized treatment options and improving patient outcomes with immune checkpoint inhibitors like pembrolizumab and nivolumab. Conversely, the small cell lung cancer (SCLC) segment is anticipated to register the fastest CAGR of 11% during the forecast period 2024-2030, driven by increasing smoking rates and greater awareness of available treatments. While traditional SCLC therapies primarily consist of chemotherapy and radiotherapy, the introduction of new treatments like immune checkpoint inhibitors is beginning to improve survival rates, leading to a surge in global demand for lung cancer therapeutics.

[pnny1-blog]

Good news the cancer is gone. Now we have to go for MRI every three months to check for it showing up somewhere else. Tim's walking is getting better. Still shaking in the evening but still better. He's not used the wheelchair in a couple weeks mostly just uses a Cain. Keep Praying God is working miracles in Tim

[luckydige45]

According to Nova One Advisor, the global non-small cell lung cancer therapeutics market size was estimated at USD 19.85 billion in 2023, USD 22.39 billion in 2024, and is expected to grow at a CAGR of 12.8% to reach USD 66.20 billion by 2033.

[soumyafwr]

Drugs for Non-small Cell Lung Cancer Market Analysis, Size, Share, and Forecast 2031

[ganitsoni]

How Lung Cancer Affects Your Body?

Dr. Chinnababu Sunkavalli, a robotic surgical oncologist, explains how lung cancer affects your body. Symptoms include a persistent cough, trouble breathing, chest pain, and fatigue. The cancer can also spread, causing more severe health issues. To Know more about Dr. Chinnababu Sunkavalli, follow his YouTube channel.

[devendrasingh3047]

How does the Avastin injection (bevacizumab) suppress intracellular tumour growth?

Avastin, known scientifically as bevacizumab, is a pivotal drug in oncology. It is known for its efficacy in suppressing intracellular tumour growth through targeted inhibition of vascular endothelial growth factor (VEGF). This blog explores the profound impact of Avastin across various cancer types, detailing its mechanism of action, clinical applications, safety profile, and future directions in cancer treatment.

What does Avastin do to cancer patients?

Avastin works by specifically binding to vascular endothelial growth factor (VEGF), a protein that stimulates the growth of new blood vessels necessary for tumour progression. Here is everything you need to know:

Inhibits Tumor Growth: Avastin (bevacizumab) works by precisely targeting and inhibiting vascular endothelial growth factor (VEGF). This protein is crucial for the formation of new blood vessels that tumours need to grow. This precise mechanism of action is what makes Avastin so effective. By blocking VEGF, Avastin reduces the blood supply to tumours, thereby slowing down their growth and potentially shrinking them.

Enhances Treatment Effectiveness: When used in combination with chemotherapy or other cancer treatments, Avastin enhances their effectiveness. By reducing the blood flow to tumours, Avastin helps other treatments penetrate tumours more effectively, improving overall treatment outcomes.

Delays Disease Progression: Avastin is known to prolong the time before cancer progresses. In clinical trials, it has been shown to increase progression-free survival rates in various types of cancers, including colorectal, lung, breast, and kidney cancers, as well as glioblastoma.

Improves Quality of Life: For many cancer patients, Avastin not only slows disease progression but also improves the quality of life by reducing symptoms associated with advanced cancer, such as pain and discomfort caused by tumour growth.

Potential Side Effects: While generally well-tolerated, Avastin can cause side effects such as hypertension, proteinuria (excess protein in the urine), bleeding, gastrointestinal perforation, and impaired wound healing. Close monitoring by healthcare providers is essential to manage these risks effectively during treatment.

What types of cancer is Avastin used for?

In clinical settings, Avastin 100mg injection is prescribed to patients with advanced stages of cancer, including colorectal, lung, breast, and kidney cancers, among others. Its effectiveness lies in its ability to disrupt the tumour's blood supply, thereby shrinking tumours and preventing their progression.

Colorectal Cancer: Avastin is approved for use in combination with chemotherapy for metastatic colorectal cancer. It helps to slow down tumour growth and improve survival rates.

Lung Cancer: In non-small cell lung cancer (NSCLC), Avastin is used as a first-line treatment in combination with chemotherapy. It has been shown to extend survival and delay disease progression.

Breast Cancer: Avastin may be used in combination with chemotherapy for metastatic HER2-negative breast cancer. It helps to reduce blood flow to tumours, potentially shrinking them and improving treatment outcomes.

Kidney Cancer: Avastin is utilised for advanced renal cell carcinoma (kidney cancer), often in combination with other targeted therapies or immunotherapy agents. It targets VEGF, which is crucial for tumour blood vessel growth.

Does Avastin have side effects?

Avastin has demonstrated significant benefits for cancer patients, especially those in advanced stages of the disease. It notably improves both progression-free survival and overall survival rates by targeting vascular endothelial growth factor (VEGF), a protein crucial for tumour blood vessel formation. 

While Avastin is generally well-tolerated, it can cause several potential side effects that require careful monitoring. Common side effects include 

Hypertension (high blood pressure)

Proteinuria (excess protein in the urine)

Bleeding tendencies

Gastrointestinal perforation (a rare but serious complication)

Impaired wound healing

How do patients respond to Avastin treatment?

While Avastin is generally well-tolerated, it can cause several potential side effects that require careful monitoring. Common side effects include hypertension (high blood pressure), proteinuria (excess protein in the urine), bleeding tendencies, gastrointestinal perforation (a rare but serious complication), and impaired wound healing. Patients undergoing Avastin treatment should be closely monitored for these side effects, and healthcare providers may adjust treatment regimens as needed to manage these risks effectively.

[corporatenews]

Explore the epidemiology analysis and forecast of non-small cell lung cancer (NSCLC) up to 2032. Stay informed about trends and projections.

[perpetualseahorse]

Wtf tumblr

[actchealth]

All You Need to Know About Non-Small Cell Lung Cancer

Lung cancer is a malignant disease that occurs due to uncontrolled growth of abnormal cells in the lung tissues. It is one of the most common and deadliest forms of cancer, primarily caused by prolonged exposure to smoking, secondhand smoke, radon gas, environmental pollutants, etc. Lung cancer can be broadly categorized into two main types based on the appearance of cancer cells under a microscope: non-small cell lung cancer (NSCLC) and small cell lung cancer.    

[pnny1-blog]

PRAISE GOD THE CANCER IS GONE!!!!!!!! Now we go every three months for MRI to watch for return and to watch for it to show up in other places. I have faith though it's gone forever. He's still shaky on his walking but improving everyday. I GIVE GOD ALL THE GLORY.

[futuretonext]

The Global Non-Small Cell Lung Cancer (NSCLC) Market is projected to grow at a CAGR of around 11.2% during the forecast period, i.e., 2022-27. Most of the market growth would be driven by the growing number of patients with Non-Small Cell Lung Cancer (NSCLC) type of lung cancer and the mounting demand for its effective diagnosis & treatment worldwide.